Monopar Therapeutics Enters Material Definitive Agreement

TL;DR

Monopar just signed a big deal, details to come.

AI Summary

Monopar Therapeutics Inc. announced on September 23, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Wilmette, IL, filed this 8-K report on September 24, 2025. Specific details of the agreement, including parties involved and financial terms, are not provided in this excerpt.

Why It Matters

This filing indicates a significant new contract or partnership for Monopar Therapeutics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the agreement introduces uncertainty.

Key Players & Entities

• Monopar Therapeutics Inc. (company) — Registrant
• September 23, 2025 (date) — Date of earliest event reported
• September 24, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Wilmette, IL (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
• $67.67 — Stock "), at a public offering price of $67.67 per share, and pre-funded warrants (the
• $67.669 — f Common Stock at the purchase price of $67.669 per Pre-Funded Warrant, which represent
• $63.6098 — its Common Stock from Tactic Pharma at $63.6098 per share, which is the same price per
• $91.9 million — enses, are expected to be approximately $91.9 million. The Offering is expected to close on S

Filing Documents

• mnpr20250924_8k.htm (8-K) — 37KB
• ex_864198.htm (EX-1.1) — 230KB
• ex_864199.htm (EX-4.1) — 88KB
• ex_864200.htm (EX-5.1) — 9KB
• ex_864201.htm (EX-10.1) — 53KB
• ex_864202.htm (EX-99.1) — 11KB
• a01.jpg (GRAPHIC) — 31KB
• a02.jpg (GRAPHIC) — 59KB
• monologo.jpg (GRAPHIC) — 4KB
• 0001437749-25-029819.txt ( ) — 779KB
• mnpr-20250923.xsd (EX-101.SCH) — 3KB
• mnpr-20250923_def.xml (EX-101.DEF) — 11KB
• mnpr-20250923_lab.xml (EX-101.LAB) — 15KB
• mnpr-20250923_pre.xml (EX-101.PRE) — 11KB
• mnpr20250924_8k_htm.xml (XML) — 3KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. Underwritten Registered Offering On September 23, 2025, Monopar Therapeutics Inc., a Delaware corporation (the " Company " or " Monopar "), entered into an Underwriting Agreement (the " Underwriting Agreement ") with Morgan Stanley & Co. LLC, Leerink Partners LLC and Barclays Capital Inc. (collectively, the " Representatives "), as Representatives of the several underwriters named therein (together with the Representatives, the " Underwriters "), pursuant to which the Company will issue and sell to the Underwriters pursuant to the Underwriting Agreement 1,034,433 shares of Common Stock, par value $0.001 per share (the " Common Stock "), at a public offering price of $67.67 per share, and pre-funded warrants (the " Pre-Funded Warrants ") to purchase 960,542 shares of Common Stock at the purchase price of $67.669 per Pre-Funded Warrant, which represents the public offering price per share for the Common Stock less a $0.001 per share exercise price (the " Offering "). The Offering is being made pursuant to a shelf registration statement filed August 29, 2025 and declared effective by the Securities and Exchange Commission (the " SEC ") on September 9, 2025 (the " Registration Statement ") (File. No. 333-289947), a base prospectus filed as part thereof, and a prospectus supplement dated September 23, 2025, filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the " Securities Act "). Each Pre-Funded Warrant will be exercisable immediately and may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of our outstanding Common Stock immediately after exercise, which percentage may be changed at the holder's election to a lower or higher percentage not in e

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure On September 23, 2025, Monopar issued a press release announcing that the Journal of Hepatology had published a peer-reviewed letter to the editor demonstrating rapidly improved copper balance in Wilson disease patients treated with Monopar's investigational therapy ALXN1840 (tiomolybdate choline). The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated September 23, 2025, by and among Monopar Therapeutics Inc., Morgan Stanley & Co. LLC, Leerink Partners LLC, and Barclays Capital Inc. 4.1 Form of Pre-Funded Warrant 5.1 Legal Opinion of Baker & Hostetler LLP 10.1 Share Purchase Agreement, dated September 24, 2025, by and between Monopar Therapeutics Inc. and Tactic Pharma, LLC. 23.1 Consent of Baker & Hostetler LLP (contained in Exhibit 5.1). 99.1 Press Release Dated September 23, 2025. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: September 24, 2025 By: /s/ Quan Vu Name: Quan Vu Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR